Equities Analysts Offer Predictions for Neogen Q1 Earnings

Neogen Co. (NASDAQ:NEOG - Free Report) - Equities researchers at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Neogen in a research note issued to investors on Wednesday, April 30th. Zacks Research analyst R. Department now forecasts that the company will earn $0.09 per share for the quarter, down from their previous forecast of $0.11. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.10 EPS, FY2026 earnings at $0.42 EPS, Q1 2027 earnings at $0.11 EPS and Q2 2027 earnings at $0.13 EPS.

Several other equities research analysts have also commented on the stock. Piper Sandler cut their price target on shares of Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 22nd. Guggenheim cut their target price on Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th.

Neogen Stock Up 11.7 %

Shares of NASDAQ:NEOG traded up $0.60 during trading on Friday, hitting $5.75. 16,432,546 shares of the company were exchanged, compared to its average volume of 2,864,059. The firm's 50 day moving average price is $7.50 and its 200-day moving average price is $10.88. Neogen has a 12-month low of $3.87 and a 12-month high of $18.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.77 and a quick ratio of 2.46. The stock has a market capitalization of $1.25 billion, a P/E ratio of -2.63 and a beta of 1.57.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its earnings results on Wednesday, April 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). The business had revenue of $221.00 million for the quarter, compared to analyst estimates of $225.27 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. Neogen's revenue was down 3.4% on a year-over-year basis. During the same period last year, the business posted $0.12 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in Neogen in the 4th quarter valued at $2,744,000. Dimensional Fund Advisors LP lifted its stake in shares of Neogen by 24.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 6,939,984 shares of the company's stock worth $84,254,000 after acquiring an additional 1,345,056 shares during the period. Norges Bank purchased a new stake in shares of Neogen in the fourth quarter valued at about $212,171,000. Vanguard Group Inc. increased its stake in shares of Neogen by 9.8% during the fourth quarter. Vanguard Group Inc. now owns 21,637,251 shares of the company's stock worth $262,676,000 after acquiring an additional 1,928,491 shares during the period. Finally, Private Advisor Group LLC raised its holdings in Neogen by 135.3% during the fourth quarter. Private Advisor Group LLC now owns 67,298 shares of the company's stock worth $817,000 after purchasing an additional 38,703 shares in the last quarter. Institutional investors and hedge funds own 96.73% of the company's stock.

Insider Activity

In other Neogen news, Director James P. Tobin acquired 10,000 shares of the company's stock in a transaction on Tuesday, April 22nd. The shares were bought at an average cost of $4.73 per share, for a total transaction of $47,300.00. Following the completion of the purchase, the director now owns 37,474 shares in the company, valued at $177,252.02. This trade represents a 36.40 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director James C. Borel bought 35,000 shares of Neogen stock in a transaction dated Thursday, April 24th. The stock was acquired at an average cost of $4.89 per share, with a total value of $171,150.00. Following the completion of the acquisition, the director now directly owns 60,474 shares of the company's stock, valued at approximately $295,717.86. The trade was a 137.39 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 67,500 shares of company stock valued at $331,525 in the last ninety days. 1.13% of the stock is currently owned by company insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.